Department of Public Health University of Turku Finland.
Institute of Biomedicine University of Turku Finland.
J Am Heart Assoc. 2020 Feb 18;9(4):e014168. doi: 10.1161/JAHA.119.014168. Epub 2020 Feb 5.
Background Lifestyle modification is a key component of cardiovascular disease prevention before and concurrently with pharmacologic interventions. We evaluated whether lifestyle factors change in relation to the initiation of antihypertensive or lipid-lowering medication (statins). Methods and Results The study population comprised 41 225 participants of the FPS (Finnish Public Sector) study aged ≥40 years who were free of cardiovascular disease at baseline and responded to ≥2 consecutive surveys administered in 4-year intervals in 2000-2013. Medication use was ascertained through pharmacy-claims data. Using a series of pre-post data sets, we compared changes in body mass index, physical activity, alcohol consumption, and smoking between 8837 initiators and 46 021 noninitiators of antihypertensive medications or statins. In participants who initiated medication use, body mass index increased more (difference in change 0.19; 95% CI, 0.16-0.22) and physical activity declined (-0.09 metabolic equivalent of task hour/day; 95% CI, -0.16 to -0.02) compared with noninitiators. The likelihood of becoming obese (odds ratio: 1.82; 95% CI, 1.63-2.03) and physically inactive (odds ratio: 1.08; 95% CI, 1.01-1.17) was higher in initiators. However, medication initiation was associated with greater decline in average alcohol consumption (-1.85 g/week; 95% CI, -3.67 to -0.14) and higher odds of quitting smoking (odds ratio for current smoking in the second survey: 0.74; 95% CI, 0.64-0.85). Conclusions These findings suggest that initiation of antihypertensive and statin medication is associated with lifestyle changes, some favorable and others unfavorable. Weight management and physical activity should be encouraged in individuals prescribed these medications.
生活方式的改变是在进行药物干预之前和同时预防心血管疾病的关键组成部分。我们评估了降压或降脂药物(他汀类药物)的起始是否与生活方式因素的变化有关。
研究人群包括 FPS(芬兰公共部门)研究中的 41225 名年龄≥40 岁的参与者,他们在基线时没有心血管疾病,并在 2000-2013 年期间以 4 年为间隔连续两次应答调查。药物使用情况通过药房数据确定。使用一系列前后数据组,我们比较了 8837 名开始使用降压药物或他汀类药物的患者和 46021 名未开始使用的患者之间体重指数、身体活动、饮酒和吸烟的变化。在开始药物治疗的患者中,体重指数增加更多(变化差异为 0.19;95%置信区间,0.16-0.22),身体活动减少(每天 0.09 代谢当量任务小时;95%置信区间,-0.16 至-0.02)与未开始的患者相比。与非起始者相比,起始者肥胖的可能性更高(优势比:1.82;95%置信区间,1.63-2.03)和身体不活跃(优势比:1.08;95%置信区间,1.01-1.17)。然而,药物的起始与平均饮酒量的下降有关(每周减少 1.85 克;95%置信区间,-3.67 至-0.14)和戒烟的可能性更高(第二次调查中当前吸烟的优势比:0.74;95%置信区间,0.64-0.85)。
这些发现表明,降压和他汀类药物的起始与生活方式的改变有关,有些是有利的,有些则不利。应该鼓励服用这些药物的个体进行体重管理和身体活动。